Abstracts

1212 – Point-of-Care Urine Tenofovir Feedback Counseling Improves PrEP Adherence for US MSM in Pilot RCT

Background Young men who have sex with men (YMSM) have high HIV incidence and challenges with PrEP adherence. Point-of-care (POC) urine tenofovir (TFV) testing permits real-time objective adherence monitoring at a low cost. A prior study with PrEP-using women in Kenya demonstrated improved long-term adherence when women had motivational interviewing (MI)-informed drug-level feedback using the…

1224 – Pre-Exposure Prophylaxis Uptake in High Female-to-Male HIV Prevalence Regions in the US

Background Despite high efficacy of pre-exposure prophylaxis (PrEP) for HIV prevention, uptake is low among cisgender women in the US, especially in the South where >50% of new HIV diagnoses occur. The Ending the HIV Epidemic (EHE) initiative prioritizes 57 jurisdictions for targeted HIV prevention and treatment interventions. To identify opportunities for optimizing HIV prevention…

1217 – Factors Associated With PrEP Uptake, Persistence, and Adherence Among Incarcerated People in Zambia

Background For justice-involved people, the times during and immediately after incarceration can be high-risk periods for HIV acquisition since these periods afford limited access/adherence to effective HIV prevention. We report results from one of the first longitudinal studies to characterize PrEP use among justice-involved people in sub-Saharan Africa. Methods From August 2023—March 2024, we enrolled…

1288 – DoxyPrEP Impact on the Microbiome of Men Who Have Sex With Men and Transgender Women on HIV PrEP

Background Doxycycline pre-exposure prophylaxis (doxyPrEP) has shown potential in preventing bacterial sexually transmitted infections (STIs) in gay, bisexual and other men who have sex with men (GBM). However, its impact on the microbiome is unknown. This study assessed rectal microbiome changes over 48 weeks in participants on HIV PrEP enrolled in a doxyPrEP trial. Methods…

1238 – Dose-Ranging Pharmacokinetics and Efficacy of a 90-Day Multipurpose IVR Delivering Islatravir

Background Multipurpose prevention technologies (MPTs) are important to protect women from unintended pregnancy and sexually transmitted infections. Uniquely designed, geometrically complex 3D printed intravaginal rings (IVRs) represent an attractive long-acting delivery platform that can provide superior control of drug release and product user characteristics. To optimize the delivery of Islatravir (ISL) within our MPT IVR…

1218 – Trends in 2016 CDC-Recommended PEP Regimens and Bictegravir for HIV PEP: United States, 2015-2023

Background Postexposure prophylaxis (PEP) is critical for HIV prevention because it is the only intervention that can prevent HIV acquisition following an exposure. 2016 CDC PEP guidelines recommend specific regimens for PEP. A recent report found increasing off-label use of bictegravir for PEP. Bictegravir is a second-generation integrase inhibitor approved for HIV treatment in 2018…